이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

고위험 비전이성 거세 저항성 전립선암(nmCRPC)을 앓는 인도 참가자를 대상으로 표준 안드로겐 차단 요법(ADT)과 함께 Darolutamide가 얼마나 안전한지, 실제 상황에서 얼마나 잘 작용하는지 자세히 알아보기 위한 연구

2026년 11월 3일 업데이트: Bayer

고위험 비전이성 거세 저항성 전립선암(nmCRPC)을 앓고 있는 인도 참가자를 위한 표준 안드로겐 박탈 요법에 추가된 Darolutamide의 단일군, 공개 라벨 4상 연구

Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors.

In men with nmCRPC, the cancer worsens despite low testosterone levels (also called castration resistant).

Prostate-specific antigen (PSA) is a protein that is made by both normal cells and by cancerous cells in the body. Thus, PSA levels can be taken as a marker for prostate cancer development.

Men with nmCRPC usually have higher levels of (PSA) than normal. They are considered "high risk" if they show signs of quickly increasing PSA levels as this could mean that the tumor is growing and might spread to other parts of the body.

The study treatment darolutamide is already available in certain countries for doctors to prescribe to men with prostate cancer that has not yet spread to other parts of the body. It works by blocking androgens from attaching to proteins in cancer cells in the prostate.

Results of a previous study in men with high-risk nmCRPC who received darolutamide in addition to ADT are already available, but this study had no Indian patients and was not conducted in India.

Therefore, the main purpose of this study is to learn how safe darolutamide is when taken in addition to ADT in Indian participants with high-risk nmCRPC.

To answer this question, the researchers will collect all medical problems the participants have that arise during the study and that may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AE). The following information regarding safety of darolutamide will be collected during the study:

  • the number and severity of AEs that are non-serious or serious
  • the number of participants who have to permanently stop the treatment due to AEs
  • the number of participants who have to change the amount of study drug taken due to AEs

AEs can be:

  • abnormal results of laboratory tests, physical examinations, or heart health examinations using ECG (detects heart problems by measuring the electrical activity generated by the heart as it contracts).
  • relevant changes in vital signs
  • relevant changes of the participant's daily living abilities (ECOG performance status)

These results will then be compared with the results from the previous study to identify any differences for this group of participants.

In addition, researchers will collect and compare data on how well darolutamide worked under real world conditions in this group of participants.

All participants will take darolutamide as tablets by mouth twice a day. The participants will visit the study center at the start of the study, and then every 16 weeks until their cancer gets worse, they develop medical problems, they leave the study or until the study is terminated.

During the study, the study team will

  • take blood and urine samples
  • do physical examinations
  • check vital signs
  • examine heart health using ECG
  • assess the participant's ECOG performance status
  • ask the participants questions about how they are feeling and what AEs they are having.

If the trial is stopped, participants may have the option to continue to receive darolutamide, provided they benefit from the treatment

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

50

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Gujarat
      • Nadiād, Gujarat, 인도, 387001
        • 모병
        • Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital)
    • Karnataka
      • Bengaluru, Karnataka, 인도, 560027
        • 모병
        • HCG Oncology Center
    • Kerala
      • Kochi, Kerala, 인도, 682041
        • 모병
        • Amrita Institute of Medical Sciences
      • Thiruvananthapuram, Kerala, 인도, 695011
        • 모병
        • Regional Cancer Centre - Thiruvananthapuram
      • Vellalasseri, Kerala, 인도, 673601
        • 모병
        • MVR Cancer Centre and Research Institute
    • Maharashtra
      • Amravati, Maharashtra, 인도, 444605
        • 모집하지 않고 적극적으로
        • Sujan Surgical Cancer Hospital & Amravati Cancer Foundation
      • Mumbai, Maharashtra, 인도, 400012
        • 모병
        • Tata Memorial Hospital
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, 인도, 110001
        • 완전한
        • Dr. RML Hospital & PGIMER
      • New Delhi, National Capital Territory of Delhi, 인도, 110085
        • 모병
        • Rajiv Gandhi Cancer Institute & Research Centre
    • Odisha
      • Bhubaneswar, Odisha, 인도, 751019
        • 모병
        • All India Institute of Medical Sciences
    • Puducherry
      • Gorimedu, Puducherry, 인도, 605006
        • 아직 모집하지 않음
        • Jawaharlal Institute Of Postgraduate Medical Education and R
    • Rajasthan
      • Jaipur, Rajasthan, 인도, 302017
        • 모병
        • Bhagwan Mahaveer Cancer Hospital & Research Centre
    • Telangana
      • Hyderabad, Telangana, 인도, 500096
        • 아직 모집하지 않음
        • Apollo Research Foundation
    • Uttar Pradesh
      • Varanasi, Uttar Pradesh, 인도, 221005
        • 모병
        • Mahamana Pandit Madan Mohan Malviya Cancer Centre
    • West Bengal
      • Kolkata, West Bengal, 인도, 700094
        • 모병
        • Netaji Subhas Chandra Bose Cancer Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • Capable of giving signed informed consent.

  • Participant must be male aged ≥ 18 years.

  • Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.

  • Castration resistance, demonstrated by:

    • a minimum of 3 rising PSA values while the participant is on continuous ADT (started at least 4 weeks prior to the PSA measurement or, PSA measured at least 4 weeks after bilateral orchiectomy) and
    • the interval between each PSA measurement must be ≥ 1 week, and
    • the PSA value at screening must be ≥ 1.0 ng/mL (1.0 μg/L). To confirm this eligibility criterion, it is acceptable for 2 out of the 3 PSA measurements to be taken during the 28-day screening period (after participant has signed consent), provided the measurements are ≥ 1 week apart. In this case, the last PSA value should be recorded as the screening value.
  • Castrate level of serum testosterone (< 1.7 nmol/L [50 ng/dL]) on gonadotropin releasing hormone (GnRH) agonist or antagonist therapy or after bilateral orchiectomy. Participants who have not undergone bilateral orchiectomy must continue GnRH therapy during the study.

  • PSA doubling time (PSADT) of ≤ 10 months.

  • Eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1.

  • Estimated glomerular filtration rate (eGFR) > 15 mL/min/1.73 m^2.

  • Blood counts at screening: hemoglobin ≥ 9.0 g/dL, absolute neutrophil count ≥ 1500/μL (1.5 × 109/L), platelet count ≥ 100,000/μL (100 ×109/L) (participant must not have received any growth factor or blood transfusion within 7 days of the hematology laboratory obtained at screening).

  • Screening values of serum alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 × upper limit of normal (ULN), total bilirubin (TBL) ≤ 1.5 × ULN (except participants with a diagnosis of Gilbert's disease), creatinine ≤ 2.0 × ULN.

  • Sexually active participants, unless surgically sterile, must agree to use a male condom plus partner use of a contraceptive method with a failure rate of <1% per year, and refrain from sperm donation during the study treatment and for 1 week after the last dose of study treatment. Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

  • History of metastatic disease at any time or presence of detectable metastases by investigator assessment within 42 days prior to start of study treatment based on standard medical imaging, i.e., computed tomography/ magnetic resonance imaging (CT/MRI) and bone scan. (Lesions seen on prostate-specific membrane antigen /positron emission tomography (PSMA/PET) scan that are not detected on standard imaging do not exclude participation.) Presence of pelvic lymph nodes < 1.5 cm in short axis below the aortic bifurcation is allowed.

  • Symptomatic local-regional disease that requires medical intervention including moderate/severe urinary obstruction or hydronephrosis due to prostate cancer.

  • Acute toxicities of prior treatments and procedures not resolved to common terminology criteria for adverse events (CTCAE) v.5.0 grade ≤ 1 or baseline before first dose of study treatment.

  • Severe or uncontrolled concurrent disease, infection, or co-morbidity that, in the opinion of the investigator, would make the participant inappropriate for enrollment.

  • Known hypersensitivity to the study treatment or any of its ingredients.

  • Major surgery within 28 days before first dose of study treatment.

  • Any of the following within 6 months before first dose of study treatment: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association Class III or IV.

  • Uncontrolled hypertension as indicated by a systolic blood pressure (BP) ≥ 160 mmHg or diastolic BP ≥ 100 mmHg at screening despite medical management. Participants with hypertension can enroll provided BP is stable and controlled by anti-hypertensive treatment.

  • End-stage renal disease (eGFR < 15 mL/min/1.73 m^2).

  • Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed ≥ 5 years ago and from which the participant has been disease-free.

  • Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.

  • Unstable active viral hepatitis with a need for treatment.

  • Known human immunodeficiency virus (HIV) infection with any of the following (Note: HIV testing is not required unless mandated by local authority):

    • CD4+ T-cell (CD4+) count of less than 350 cells/μL
    • History of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months
    • On established antiretroviral therapy for less than 4 weeks
    • Presenting with a viral load of more than 400 copies/mL prior to enrollment
    • On antiretroviral therapy or prophylactic antimicrobials that are expected to cause significant drug-drug interactions or overlapping toxicities with study treatment and cannot be changed to alternative agents.
  • Any condition that, in the opinion of the investigator, would impair the participants' ability to comply with the study procedures or study treatment (e.g., unable to swallow study treatment).

  • Unwilling or unable to comply with all protocol-required visits and assessments or comply with study requirements.

  • Prior treatment with:

    • Second-generation androgen receptor (AR) inhibitors (such as enzalutamide, apalutamide, darolutamide, proxalutamide, etc)
    • Other investigational AR inhibitors
    • Cytochrome P450 (CYP17) enzyme inhibitors (such as oral ketoconazole, abiraterone acetate, TAK-700, etc).
  • Use of first-generation AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) within 28 days before first dose of study treatment.

  • Use of estrogens or 5-α reductase inhibitors (finasteride, dutasteride) within 28 days before first dose of study treatment.

  • Prior chemotherapy or immunotherapy for prostate cancer, except adjuvant/neoadjuvant treatment completed > 2 years before first dose of study treatment.

  • Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days before first dose of study treatment.

  • Radiation therapy (external beam radiation therapy, brachytherapy, or radiopharmaceuticals) within 12 weeks before first dose of study treatment.

  • Treatment with an osteoclast-targeted therapy (bisphosphonate or denosumab) to prevent skeletal-related events within 4 weeks before first dose of study treatment. Participants receiving osteoclast-targeted therapy to prevent bone loss at a dose and schedule indicated for osteoporosis may continue treatment at the same dose and schedule.

  • Treatment with any investigational drug within 28 days before first dose of study treatment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Darolutamide (BAY1841788)

Participants with high-risk nmCRPC will receive darolutamide.

600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
AE로 인해 연구 치료가 중단된 참가자 수
기간: 약 15개월
약 15개월
AE로 인해 연구 치료의 용량이 조정된 참가자 수
기간: 약 15개월
약 15개월
실험실 매개변수에서 임상적으로 유의미한 이상이 있는 참가자 수
기간: 약 15개월
약 15개월
임상적으로 유의미한 심전도 이상이 있는 참가자 수
기간: 약 15개월
약 15개월
임상적으로 유의미한 신체 검사 이상이 있는 참가자 수
기간: 약 15개월
약 15개월
활력 징후에 임상적으로 유의미한 변화가 있는 참가자 수
기간: 기준선에서 약 15개월까지
기준선에서 약 15개월까지
동부 협력 종양학 그룹(ECOG) 수행 상태가 변경된 참가자 수
기간: 기준선에서 약 15개월까지
기준선에서 약 15개월까지
부작용 (AES) 및 심각한 부작용 (SAE) 및 심각도를 가진 참가자 수.
기간: 약 15 개월.
약 15 개월.

2차 결과 측정

결과 측정
기간
기준선에서 16주까지의 전립선 특이 항원(PSA) 백분율 변화
기간: 기준선에서 16주까지
기준선에서 16주까지
연구 치료 중 언제든지 기준선에서 PSA 최대 퍼센트 감소
기간: 기준선에서 약 15개월까지
기준선에서 약 15개월까지
첫 번째 후속 전신 항신생물 요법 시작까지의 시간
기간: 약 15개월에
약 15개월에
전립선암에 대한 첫 번째 세포독성 화학요법 시작까지의 시간
기간: 약 15개월에
약 15개월에

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 8월 3일

기본 완료 (추정된)

2027년 12월 30일

연구 완료 (추정된)

2027년 12월 30일

연구 등록 날짜

최초 제출

2022년 4월 21일

QC 기준을 충족하는 최초 제출

2022년 4월 21일

처음 게시됨 (실제)

2022년 4월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 8월 14일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • 21707

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .